Evidence map›Paper›PMID 39360943›Full record

Trial reportFuture oncology (London, England)2024

Efficacy in patients with

Xingxiang Pu, Juan Li, Bo Zhang, Jinyao Zhang, Tony S K Mok, Kazuhiko Nakagawa, Rafael Rosell, Ying Cheng, Xiangdong Zhou, Maria Rita Miglorino and 10 more

Abstract readMulticenter StudyClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xingxiang PuSecond Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Juan LiDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610000, China.
Bo ZhangShanghai Chest Hospital, Jiao Tong University, Shanghai, 200025, China.
Jinyao ZhangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.
Tony S K MokDepartment of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 999077, China.
Kazuhiko NakagawaDepartment of Medicine, Kindai University Hospital, Osaka, 589-8511, Japan.
Rafael RosellDr. Rosell Oncology Institute & Quirón-Dexeus University Institute, Barcelona, 08028, Spain.
Ying ChengJilin Provincial Cancer Hospital, Changchun, China.
Xiangdong ZhouFirst Affiliated Hospital of Third Military Medical University, Chongqing, 400038, China.
Maria Rita MiglorinoPneumological Oncology, San Camillo Forlanini Hospital, Roma, 00152, Italy.
Seiji NihoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 2778577, Japan.
Ki Hyeong LeeChungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, 28644, South Korea.
Jesus CorralClínica Universidad de Navarra, Madrid, 28027, Spain.
Adam PluzanskiMaria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-034, Poland.
Junling LiDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.
Rolf LinkeSFJ Pharmaceuticals Inc., Pleasanton, CA 94588, USA.
Fang PanPfizer, Beijing, 100010, China.
Yiyun TangPfizer, San Diego, CA 92121, USA.
Weiwei TanPfizer, San Diego, CA 92121, USA.
Lin WuSecond Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.ORCID 0000-0001-7078-7767

Funding

PfizerSFJ Pharmaceuticals
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsQuinazolinonesAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedMutationProgression-Free SurvivalProtein Kinase InhibitorsTreatment OutcomeAntineoplastic AgentsdacomitinibEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsQuinazolinonesARCHER 1050biomarkerdacomitinibnon-small-cell lung cancerskin disorders

Identifiers

PMID39360943
PMCPMC11572312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.